A phase II study of TFTD plus Bevacizumab in patients with unresectable advanced colorectal cancer

ABSTRACT: Interventions: TFTD: fixed dose Bevacizumab: fixed dose Primary outcome(s): Time to treatment failure Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Advanced Colorectal Cancer

PROVIDER: 2650700 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR